市場調査レポート

商品コード

1771290

DNA損傷応答市場：業界動向と世界の予測 - 適応疾患別、治療領域別、標的分子別、分子タイプ別、投与経路別、主要地域別

DNA Damage Response Market: Industry Trends and Global Forecasts - Distribution by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of Administration, and Key Geographical Regions

出版日: 2025年07月15日
発行: Roots Analysis
ページ情報: 英文 265 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,799 707,756円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (One-Location Site License)

USD 6,999 1,032,212円

レポートPDFを同一所在地における特定事業ユニットに属する全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Department License)

USD 10,599 1,563,140円

レポートPDFを部署単位で12名様までご利用いただけるライセンスです。同一部署内であれば、地理的に同じ地点に存在する必要はありません。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 17,999 2,654,492円

レポートPDFを同社の国内外拠点における全ての方にてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.48円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のDNA損傷応答市場：概要

世界のDNA損傷応答市場の市場規模は、今年1,300万米ドルとなりました。同市場は、予測期間中に有利なCAGRで成長すると予測されています。

市場セグメンテーションと機会分析は、以下のパラメータでセグメント化されています：

適応疾患

急性骨髄性白血病
COVID-19
糖尿病黄斑浮腫
中皮腫
骨髄異形成症候群
非扁平上皮非小細胞肺がん
前立腺がん
子宮漿液性がん

治療領域

血液悪性腫瘍
固形がん
その他

標的分子

APE1/Ref-1
カゼインキナーゼ2
CHK-1
C-Tak
DHODH
MAPKAPK2
p53
WEE 1

分子タイプ

生物製剤
低分子

投与経路

経口薬
静脈注射薬

主要地域

北米（米国、カナダ）
欧州（デンマーク、フランス、ドイツ、イタリア、スペイン、英国）
アジア太平洋（オーストラリア、シンガポール、韓国）

世界のDNA損傷応答市場：成長と動向

DNA損傷応答（DDR）は、DNA損傷の修復を促進するだけでなく、細胞周期のチェックポイントを活性化する経路の協調ネットワークで構成されています。これは、ゲノム全体の完全性を維持するために、重要な段階での細胞周期の停止につながります。特に、損傷が修復不可能な場合、この複雑なシステムは、細胞が分裂を受ける前に遺伝物質を修復するか、突然変異の伝播を防ぐためにプログラムされた細胞死を促進することを確実にします。さらに、従来の治療法に対する特異性と感度が高く、標的外毒性が低いことから、DDRは、腫瘍性疾患と非腫瘍性疾患の両方を含む広範な臨床症状に対する有望な治療標的となっています。その結果、世界中の研究者が、DNAに損傷を与える抗がん剤治療に対するDDR媒介抵抗性に対抗するため、また代替経路を標的とすることによってがんにおけるDDR機能障害を利用するために、DDR阻害剤を開発しています。

DNA損傷修復プロセスを標的とする4種類のポリADPリボースポリメラーゼ（PARP）阻害薬が、現在進行期のがん治療薬として承認されていることは特筆に値します。さらに、世界中の医薬品開発者は、ATM、ATR、CHK1、WEE1など、DNA損傷応答経路内の他の分子標的を研究しています。

世界のDNA損傷応答市場：主要インサイト

当レポートは、世界のDNA損傷応答市場の現状を掘り下げ、業界における潜在的な成長機会を明らかにします。当レポートの主な調査結果は以下の通りです。

現在、45社近くの企業が、様々な臨床症状を治療するためにDNA損傷応答（DDR）を標的とした治療薬の開発に従事しています。
パイプラインの薬剤候補の大半は開発の初期段階にあり、これらは主に様々ながん疾患の特徴である生体分子上のエピトープを標的とするように設計されています。
DDRを標的とする治療薬の前臨床パイプラインは充実しており、成長中です。これらの薬剤候補の大半（75％以上）は低分子です。
ATRを標的とする薬剤候補の70％以上が臨床試験中であり、そのような介入の約55％は経口投与用に設計されています。
固形がんの治療を目的としたDDR標的薬の約65％は、すでに前臨床試験で概念実証がなされています。
2010年以降、DDRを標的とする治療法の有効性を評価するために220以上の臨床試験が登録されたが、このような試験の平均完了期間はアジア太平洋では比較的短かくなっています。

この分野におけるイノベーションは、一流ジャーナルに掲載された多数の科学論文からも明らかです。現在の焦点は、特に異なるタイプのがんに対する新規ターゲットの同定にあるようです。
この分野の論文数は過去1年間で大幅に増加しており、論文の約30％は2021年以降に発表されたものです。
発表された論文／記事によると、現在の研究活動の焦点は、ATR、ADP、ATR、HSPなどの標的分子です。
白血病、肺がん、卵巣がんなどの、がんに対するDDR標的療法に焦点を当てた研究が明らかに増加しています。
開発の初期段階から薬剤の上市に至るまで、いくつかのパラメータが価格設定や採用率に影響します。開発者は競争を勝ち抜くために、これらすべての要因の組み合わせを考慮しなければならないです。
競争上の優位性を追求し、多くの消費者層を獲得するためには、イノベーターは自社製品の採用と価格設定に直接的・間接的な影響を与える要因の両方を理解することが不可欠です。
有望な治療薬の開発パイプラインと有望な臨床研究成果を考慮すると、DDR標的治療薬市場は2035年まで年率換算で大幅な成長が見込まれます。
予測される市場機会は、さまざまな標的疾患の適応症、投与経路、主要な地域にわたって十分に分散している可能性が高いです。

DNA損傷応答市場の参入企業例

Aprea Therapeutics
AstraZeneca
Chordia Therapeutics
Mission Therapeutics
Repare Therapeutics
Senhwa Biosciences

世界のDNA損傷応答市場

市場規模と機会分析：この調査レポートは、世界のDNA損傷応答市場を詳細に分析し、[A]適応疾患、[B]治療領域、[C]標的分子、[D]分子タイプ、[E]投与経路、[F]主要地域などの主要市場セグメントに焦点を当てています。
市場情勢：A]開発段階、[B]適応疾患、[C]治療領域、[D]標的分子、[E]分子タイプ、[F]治療タイプ、[G]剤形、[H]投与経路、[I]特効薬指定（もしあれば）など、様々なパラメータを考慮したDNA損傷応答標的治療薬の包括的評価。さらに、[A]設立年、[B]企業規模（従業員数）、[C]本社所在地に基づいて、DNA損傷応答標的治療薬の開発に従事する企業を包括的に評価します。
主要な洞察A】DNA損傷応答市場に従事する主要企業を比較するバブル分析、【B】DNA損傷応答標的治療薬開発企業をその標的治療領域と企業規模に基づいて分析、【C】DNA損傷応答市場に従事する開発企業の地域分布を強調する詳細分析、【D】DNA損傷応答標的治療薬の分布を示す包括的分析など、4つの図式を用いて現代の市場動向を洞察的に分析しています。
企業プロファイル：A]企業概要、[B]各薬剤候補に関連する詳細、[C]最近の動向と情報に基づく将来の見通しに焦点を当てた、DNA損傷応答標的治療薬の開発に携わる企業の詳細なプロファイル。
臨床試験分析：A]臨床試験登録年、[B]登録患者数、[C]登録患者の性別、[D]臨床試験のフェーズ、[E]募集状況および試験デザイン、[F]主要な（実施された臨床試験数における）スポンサー/共同研究者および主要な参入企業、[G]組織の種類、[H]人気のある治療領域、[i]臨床試験の地域分布など、様々な関連パラメータに基づき、様々なDNA損傷応答標的治療薬に関する250以上の完了済み、進行中、および計画中の臨床試験を詳細に分析。
論文分析：A]出版年、[B]出版タイプ、[C]主要研究拠点、[D]最も人気のある著者、[E]授与された助成金の提供、[F]標的分子、[G]最も人気のあるジャーナルに基づいて、DNA損傷応答ターゲティング調査に関連する150以上の査読付き科学論文を洞察的に分析。

当レポートでは、世界のDNA損傷応答市場について調査し、市場の概要とともに、適応疾患別、治療領域別、標的分子別、分子タイプ別、投与経路別動向、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

章の概要
ポートフォリオの強さ、開発段階、企業規模別分析（4Dバブルチャート）
治療領域と企業規模別の分析（ツリーマップ表示）
本社所在地別分析（世界地図表示）
開発段階、治療領域、分子タイプ、治療法の種類、投与経路別分析（グリッド表示）

第6章企業プロファイル

章の概要
Aprea Therapeutics
AstraZeneca
Chordia Therapeutics
Mission Therapeutics
Repare Therapeutics
Senhwa Biosciences

第7章臨床試験の分析

章の概要
範囲と調査手法
DNA損傷応答標的治療薬：臨床試験分析

第8章出版物の分析

章の概要
範囲と調査手法
DNA損傷応答標的治療薬：最近の出版物一覧

第9章医薬品の価格と採用に影響を与える主要なパラメータの分析

章の概要
主要な市場促進要因
ルーツ分析フレームワーク

第10章市場予測

章の概要
範囲と制限
予測調査手法と主要な前提条件
2035年までの世界のDNA損傷応答標的治療薬市場
- DNA損傷応答標的治療薬市場：適応疾患別
- DNA損傷応答標的治療薬市場：治療領域別
- DNA損傷応答標的治療薬市場：標的分子別
- DNA損傷応答標的治療薬市場：分子タイプ別
- DNA損傷応答標的治療薬市場：投与経路別
- DNA損傷応答標的治療薬市場：地域別
- 医薬品別売上予測
- 結論

第11章結論

第12章付録I：表形式データ

第13章付録II：企業および組織の一覧

図表

List of Tables

Table 3.1 Key Components of DNA Repair System
Table 3.2 Comparison of HRR and NHEJ DNA Damage Repair Pathways
Table 3.3 DNA Damage Repair Related Inherited Mutations
Table 4.1 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Phase of Development, Target Disease Indication(s), and Therapeutic Area
Table 4.2 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Target Molecule, Type of Molecule, and Type of Therapy
Table 4.3 DNA Damage Response Targeting Therapeutics (Clinical Pipeline): Information on Dosage Form, Route of Administration, and Special Drug Designation Awarded
Table 4.4 DNA Damage Response Targeting Therapeutics (Preclinical Pipeline): Information on Phase of Development, Target Disease Indication(s), and Therapeutic Area
Table 4.5 DNA Damage Response Targeting Therapeutics (Preclinical Pipeline): Information on Target Molecule, Type of Molecule, Type of Therapy and Dosage Form
Table 4.6 DNA Damage Response Targeting Therapeutics: List of Drug Developers
Table 6.1 DNA Damage Response Targeting Therapeutics: List of Companies Profiled
Table 6.2 Aprea Therapeutics: Company Overview
Table 6.3 Aprea Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.4 Aprea Therapeutics: Recent Developments and Future Outlook
Table 6.5 AstraZeneca: Company Overview
Table 6.6 AstraZeneca: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.7 AstraZeneca: Recent Developments and Future Outlook
Table 6.8 Chordia Therapeutics: Company Overview
Table 6.9 Chordia Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.10 Chordia Therapeutics: Recent Developments and Future Outlook
Table 6.11 Mission Therapeutics: Company Overview
Table 6.12 Mission Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.13 Mission Therapeutics: Recent Developments and Future Outlook
Table 6.14 Repare Therapeutics: Company Overview
Table 6.15 Repare Therapeutics: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.16 Repare Therapeutics: Recent Developments and Future Outlook
Table 6.17 Senhwa Biosciences: Company Overview
Table 6.18 Senhwa Biosciences: DNA Damage Response Targeting Therapeutics Portfolio
Table 6.19 Senhwa Biosciences: Recent Developments and Future Outlook
Table 8.1 List of Recent Publications, Since 2020
Table 8.2 Publication Analysis: List of Most Valued Publications
Table 10.1 DNA Damage Response Targeting Therapeutics: Promising Drug Candidates
Table 10.2 DNA Damage Response Targeting Therapeutics Forecast Assumptions: Price Estimations in Key Geographies
Table 10.3 Adavosertib (AZD1775, MK-1775), AstraZeneca: Target Patient Population
Table 10.4 Adavosertib (AZD1775, MK-1775), AstraZeneca: Net Present Value (USDMillion)
Table 10.5 Adavosertib (AZD1775, MK-1775), AstraZeneca: Value Creation Analysis (USDMillion)
Table 10.6 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Target Patient Population
Table 10.7 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Net Present Value (USDMillion)
Table 10.8 ASLAN003 (LAS 186323, Aslan Pharmaceuticals: Value Creation Analysis (USD Million)
Table 10.9 CBP-501, CanBas: Target Patient Population
Table 10.10 CBP-501, CanBas: Net Present Value (USD Million)
Table 10.11 CBP-501, CanBas: Value Creation Analysis (USD Million)
Table 10.12 Eprenetapopt (APR-246), Aprea Therapeutics: Target Patient Population
Table 10.13 Eprenetapopt (APR-246), Aprea Therapeutics: Net Present Value (USD Million)
Table 10.14 Eprenetapopt, (APR-246) Aprea Therapeutics: Value Creation Analysis (USD Million)
Table 10.15 Irofulven, Allarity Therapeutics: Target Patient Population
Table 10.16 Irofulven, Allarity Therapeutics: Net Present Value (USD Million)
Table 10.17 Irofulven, Allarity Therapeutics: Value Creation Analysis (USD Million)
Table 10.18 LB-100, Lixte Biotechnology: Target Patient Population
Table 10.19 LB-100, Lixte Biotechnology: Net Present Value (USD Million)
Table 10.20 LB-100, Lixte Biotechnology: Value Creation Analysis (USD Million)
Table 10.21 Sapacitabine, Cyclacel Pharmaceuticals: Target Patient Population
Table 10.22 Sapacitabine, Cyclacel Pharmaceuticals: Net Present Value (USD Million)
Table 10.23 Sapacitabine, Cyclacel Pharmaceuticals: Value Creation Analysis (USD Million)
Table 10.24 Silmitasertib, Senhwa Biosciences: Target Patient Population
Table 10.25 Silmitasertib, Senhwa Biosciences: Net Present Value (USD Million)
Table 10.26 Silmitasertib, Senhwa Biosciences: Value Creation Analysis (USD Million)
Table 10.27 TRC-102, TRACON Pharmaceuticals: Target Patient Population
Table 10.28 TRC-102, TRACON Pharmaceuticals: Net Present Value (USD Million)
Table 10.29 TRC-102, TRACON Pharmaceuticals: Value Creation Analysis (USD Million)
Table 12.1 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development
Table 12.2 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.3 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Table 12.4 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Therapeutic Area
Table 12.5 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.6 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule
Table 12.7 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Table 12.8 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Molecule
Table 12.9 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule and Type of Molecule
Table 12.10 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Therapy
Table 12.11 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Dosage Form
Table 12.12 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Route of Administration
Table 12.13 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Table 12.14 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.15 DNA Damage Response Targeting Therapeutics: (Preclinical-stage Drug Candidates) Distribution by Phase of Development and Target Disease Indication(s)
Table 12.16 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Table 12.17 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.18 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Therapy
Table 12.19 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Dosage Form
Table 12.20 DNA Damage Response Targeting Therapeutics Developers: Distribution by Year of Establishment
Table 12.21 DNA Damage Response Targeting Therapeutics Developers: Distribution by Company Size
Table 12.22 DNA Damage Response Targeting Therapeutics Developers: Distribution by Location of Headquarters
Table 12.23 Leading Developers: Distribution by Number of DNA Damage Response Targeting Therapeutics
Table 12.24 4D Bubble Analysis: Distribution by Portfolio Strength, Target Molecule, Phase of Development and Company Size
Table 12.25 Treemap Representation: Distribution by Therapeutic Area and Company Size
Table 12.26 World Map Representation: Distribution by Location of Headquarters
Table 12.27 Grid Representation: Distribution by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration
Table 12.28 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since 2011
Table 12.29 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Registration Year, Since 2011
Table 12.30 Clinical Trial Analysis: Distribution of Patients Enrolled by Gender
Table 12.31 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.32 Clinical Trial Analysis: Distribution by Year wise Distribution by Trial Phase
Table 12.33 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Table 12.34 Clinical Trial Analysis: Year wise Distribution of Patients Enrolled by Trial Phase
Table 12.35 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Table 12.36 Clinical Trial Analysis: Distribution by Recruitment Status
Table 12.37 Clinical Trial Analysis: Cumulative Year-wise Trend by Recruitment Status
Table 12.38 Clinical Trial Analysis: Distribution by Study Design
Table 12.39 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 12.40 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 12.41 Clinical Trial Analysis: Year wise Distribution by Most Popular Therapeutic Areas
Table 12.42 Clinical Trial Analysis: Cumulative Year wise Trend of Patients Enrolled by Most Popular Therapeutic Areas
Table 12.43 Clinical Trial Analysis: Distribution by Therapeutic Area and Average Completion Time
Table 12.44 Clinical Trial Analysis: Regional Distribution of Patients Enrolled by Gender
Table 12.45 Clinical Trial Analysis: Regional Distribution by Trial Phase and Average Completion Time
Table 12.46 Clinical Trial Analysis: Regional Distribution by Therapeutic Area and Average Completion Time
Table 12.47 Clinical Trial Analysis: Regional Distribution by Patients Enrolled
Table 12.48 Clinical Trial Analysis: Regional Distribution by Average Completion Time
Table 12.49 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Table 12.50 Leading Industry Players: Distribution by Number of Clinical Trials
Table 12.51 Clinical Trial Analysis: Concluding Remarks
Table 12.52 Publications Analysis: Distribution by Year of Publication
Table 12.53 Publications Analysis: Distribution by Type of Publication
Table 12.54 Key Journals: Distribution by Number of Publications
Table 12.55 Publications Analysis: Distribution by Journal Impact Factor
Table 12.56 Key Journals: Distribution by Journal Impact Factor
Table 12.57 Key Research Hubs: Distribution by Number of Publications
Table 12.58 Publications Analysis: Distribution by Target Molecule
Table 12.59 Publications Analysis: Distribution by Year wise Distribution by Most Popular Target Molecules
Table 12.60 Locations of Grant Awarding Organizations: Distribution by Number of Publications
Table 12.61 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.62 DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication
Table 12.63 DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.64 DNA Damage Response Targeting Therapeutics Market for COVID-19, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.65 DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.66 DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.67 DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.68 DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.69 DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.70 DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.71 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area
Table 12.72 DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.73 DNA Damage Response Targeting Therapeutics Market for Solid Tumors, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.74 DNA Damage Response Targeting Therapeutics Market for Other Disorders, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.75 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule
Table 12.76 Damage Response Targeting Therapeutics Market for APE1/Ref-1, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.77 Damage Response Targeting Therapeutics Market for Casein Kinase 2, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.78 Damage Response Targeting Therapeutics Market for CHK-1, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.79 Damage Response Targeting Therapeutics Market for C-Tak, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.80 Damage Response Targeting Therapeutics Market for DHODH, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.81 Damage Response Targeting Therapeutics Market for MAPKAPK2, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.82 Damage Response Targeting Therapeutics Market for p53, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.83 Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A Market, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.84 Damage Response Targeting Therapeutics Market for WEE 1, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.85 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule
Table 12.86 DNA Damage Response Targeting Therapeutics Market for Biologics, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.87 DNA Damage Response Targeting Therapeutics Market for Small Molecules, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.88 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration
Table 12.89 DNA Damage Response Targeting Therapeutics Market for Oral Drugs, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.90 DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.91 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Geography
Table 12.92 DNA Damage Response Targeting Therapeutics Market in the US, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.93 DNA Damage Response Targeting Therapeutics Market in the Canada, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.94 DNA Damage Response Targeting Therapeutics Market in the Denmark, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.95 DNA Damage Response Targeting Therapeutics Market in France, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.96 DNA Damage Response Targeting Therapeutics Market in Germany, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.97 DNA Damage Response Targeting Therapeutics Market in Italy, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.98 DNA Damage Response Targeting Therapeutics Market in Spain, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.99 DNA Damage Response Targeting Therapeutics Market in the UK, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.100 DNA Damage Response Targeting Therapeutics Market in Australia, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.101 DNA Damage Response Targeting Therapeutics Market in Singapore, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.102 DNA Damage Response Targeting Therapeutics Market in South Korea, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.103 Adavosertib (AZD1775, MK-1775), AstraZeneca: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 12.104 APX3330, Apexian Pharmaceuticals: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.105 ASLAN003 (LAS 186323), Aslan Pharmaceuticals: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.106 CBP-501, CanBas: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.107 Eprenetapopt, Aprea Therapeutics: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.108 Irofulven, Allarity Therapeutics: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.109 LB-100, Lixte Biotechnology: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.110 Silmitasertib, Senhwa Biosciences: Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Table 12.111 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, Till 2035: Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

Figure 3.1 Type of DNA Damage
Figure 3.2 Types of Causative Agents for DNA Damage
Figure 3.3 DNA Damage Causative Agents and Associated Repair System
Figure 3.4 DNA Damage Response System
Figure 3.5 Direct DNA Damage Repair Systems
Figure 3.6 Key Steps Involved in Base Excision Repair Pathway
Figure 3.7 Key Steps Involved in Nucleotide Excision Repair Pathway
Figure 3.8 Key Steps Involved in Mismatch Repair Pathway
Figure 3.9 Key Steps Involved in Homologous Recombination Repair Pathway
Figure 3.10 Key Steps Involved in Non-Homologous Repair Pathway
Figure 4.1 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development
Figure 4.2 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.3 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.4 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Therapeutic Area
Figure 4.5 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution Phase of Development and Therapeutic Area
Figure 4.6 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule
Figure 4.7 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Figure 4.8 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Molecule
Figure 4.9 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Target Molecule and Type of Molecule
Figure 4.10 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Type of Therapy
Figure 4.11 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Dosage Form
Figure 4.12 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Route of Administration
Figure 4.13 DNA Damage Response Targeting Therapeutics (Clinical-stage Drug Candidates): Distribution by Special Drug Designation Awarded
Figure 4.14 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Figure 4.15 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.16 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.17 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Figure 4.18 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Figure 4.19 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Therapy
Figure 4.20 DNA Damage Response Targeting Therapeutics (Preclinical-stage Drug Candidates): Distribution by Dosage Form
Figure 4.21 DNA Damage Response Targeting Therapeutics Developers: Distribution by Year of Establishment
Figure 4.22 DNA Damage Response Targeting Therapeutics Developers: Distribution by Company Size
Figure 4.23 DNA Damage Response Targeting Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.24 Leading Developers: Distribution by Number of DNA Damage Response Targeting Therapeutics
Figure 5.1 4D Bubble Representation: Distribution by Portfolio Strength, Target Molecule, Phase of Development and Company Size
Figure 5.2 Treemap Representation: Distribution by Therapeutic Area and Company Size
Figure 5.3 World Map Representation: Distribution by Location of Headquarters
Figure 5.4 Grid Representation: Distribution by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Since 2011
Figure 7.3 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Registration Year, Since 2011
Figure 7.4 Clinical Trial Analysis: Distribution of Patients Enrolled by Gender
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.6 Clinical Trial Analysis: Year wise Distribution by Trial Phase
Figure 7.7 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Phase
Figure 7.8 Clinical Trial Analysis: Year wise Distribution of Patients Enrolled by Trial Phase
Figure 7.9 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Figure 7.10 Clinical Trial Analysis: Distribution by Recruitment Status
Figure 7.11 Clinical Trial Analysis: Cumulative Year wise Distribution by Recruitment Status
Figure 7.12 Clinical Trial Analysis: Distribution by Study Design
Figure 7.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.14 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15 Clinical Trial Analysis: Year wise Distribution by Most Popular Therapeutic Areas
Figure 7.16 Clinical Trial Analysis: Cumulative Year wise Trend of Patients Enrolled by Most Popular Therapeutic Areas
Figure 7.17 Clinical Trial Analysis: Distribution by Therapeutic Area and Average Completion Time
Figure 7.18 Clinical Trial Analysis: Regional Distribution
Figure 7.19 Clinical Trial Analysis: Regional Distribution by Trial Phase and Average Completion Time
Figure 7.20 Clinical Trial Analysis: Regional Distribution by Therapeutic Area and Average Completion Time
Figure 7.21 Clinical Trial Analysis: Regional Distribution by Patients Enrolled
Figure 7.22 Clinical Trial Analysis: Regional Distribution by Average Completion Time
Figure 7.23 Clinical Trial Analysis: Year wise Distribution by Trial Phase and Average Completion Time
Figure 7.24 Leading Industry Players: Distribution by Number of Clinical Trials
Figure 7.25 Clinical Trial Analysis: Concluding Remarks
Figure 8.1 Publications Analysis: Methodology
Figure 8.2 Publications Analysis: Distribution by Year of Publication
Figure 8.3 Publications Analysis: Distribution by Type of Publication
Figure 8.4 Publications Analysis: Emerging Focus Areas
Figure 8.5 Key Journals: Distribution by Number of Publications
Figure 8.6 Publications Analysis: Distribution by Journal Impact Factor
Figure 8.7 Key Journals: Distribution by Journal Impact Factor
Figure 8.8 Key Research Hubs: Distribution by Number of Publications
Figure 8.9 Publications Analysis: Distribution by Target Molecule
Figure 8.10 Publications Analysis: Year wise Distribution by Most Popular Target Molecules
Figure 8.11 Locations of Grant Awarding Organizations: Distribution by Number of Publications
Figure 8.12 Publications Analysis: Multivariate Benchmark Analysis
Figure 9.1 Key Parameters Impacting Drug Pricing and Adoption
Figure 9.2 Adavosertib (AZD1775) (MK-1775)
Figure 9.3 APX3330
Figure 9.4 ASLAN003
Figure 9.5 CBP-501
Figure 9.5 Eprenetapopt
Figure 9.6 Irofulven
Figure 9.7 LB-100
Figure 9.8 Silmitasertib
Figure 9.9 TRC-102
Figure 10.1 Global DNA Damage Response Targeting Therapeutics Market, Conservative, Base and Optimistic Scenarios, Till 2035 (USD Million)
Figure 10.2 DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication
Figure 10.3 DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, Till 2035 (USD Million)
Figure 10.4 DNA Damage Response Targeting Therapeutics Market for COVID-19, Till 2035 (USD Million)
Figure 10.5 DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, Till 2035 (USD Million)
Figure 10.6 DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, Till 2035 (USD Million)
Figure 10.7 DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, Till 2035 (USD Million)
Figure 10.8 DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, Till 2035 (USD Million)
Figure 10.9 DNA Damage Response Targeting Therapeutics Market for Prostate Cancer, Till 2035 (USD Million)
Figure 10.10 DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, Till 2035 (USD Million)
Figure 10.11 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area
Figure 10.12 DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, Till 2035 (USD Million)
Figure 10.13 DNA Damage Response Targeting Therapeutics Market for Solid Tumors, Till 2035 (USD Million)
Figure 10.14 DNA Damage Response Targeting Therapeutics Market for Other Disorders, Till 2035 (USD Million)
Figure 10.15 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule
Figure 10.16 DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, Till 2035 (USD Million)
Figure 10.17 DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, Till 2035 (USD Million)
Figure 10.18 DNA Damage Response Targeting Therapeutics Market for CHK-1, Till 2035 (USD Million)
Figure 10.19 DNA Damage Response Targeting Therapeutics Market for C-Tak, Till 2035 (USD Million)
Figure 10.20 DNA Damage Response Targeting Therapeutics Market for DHODH, Till 2035 (USD Million)
Figure 10.21 DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, Till 2035 (USD Million)
Figure 10.22 DNA Damage Response Targeting Therapeutics Market for p53, Till 2035 (USD Million)
Figure 10.23 DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, Till 2035 (USD Million)
Figure 10.24 DNA Damage Response Targeting Therapeutics Market for WEE 1, Till 2035 (USD Million)
Figure 10.25 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule
Figure 10.26 DNA Damage Response Targeting Therapeutics Market for Biologics, Till 2035 (USD Million)
Figure 10.27 DNA Damage Response Targeting Therapeutics Market for Small Molecules, Till 2035 (USD Million)
Figure 10.28 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration
Figure 10.29 DNA Damage Response Targeting Therapeutics Market for Oral Drugs, Till 2035 (USD Million)
Figure 10.30 DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, Till 2035 (USD Million)
Figure 10.31 Global DNA Damage Response Targeting Therapeutics Market: Distribution by Geography
Figure 10.32 DNA Damage Response Targeting Therapeutics Market in the US, Till 2035 (USD Million)
Figure 10.33 DNA Damage Response Targeting Therapeutics Market in Canada, Till 2035 (USD Million)
Figure 10.34 DNA Damage Response Targeting Therapeutics Market in Denmark, Till 2035 (USD Million)
Figure 10.35 DNA Damage Response Targeting Therapeutics Market in France, Till 2035 (USD Million)
Figure 10.36 DNA Damage Response Targeting Therapeutics Market in Germany, Till 2035 (USD Million)
Figure 10.37 DNA Damage Response Targeting Therapeutics Market in Italy, Till 2035 (USD Million)
Figure 10.38 DNA Damage Response Targeting Therapeutics Market in Spain, Till 2035 (USD Million)
Figure 10.39 DNA Damage Response Targeting Therapeutics Market in the UK, Till 2035 (USD Million)
Figure 10.40 DNA Damage Response Targeting Therapeutics Market in Australia, Till 2035 (USD Million)
Figure 10.41 DNA Damage Response Targeting Therapeutics Market in Singapore, Till 2035 (USD Million)
Figure 10.42 DNA Damage Response Targeting Therapeutics Market in South Korea, Till 2035 (USD Million)
Figure 10.43 Adavosertib (AZD1775, MK-1775), AstraZeneca: Sales Forecast, till 2030 (USD Million)
Figure 10.44 APX3330, Apexian Pharmaceuticals: Sales Forecast, till 2030 (USD Million)
Figure 10.45 ASLAN003 (LAS 186323), Aslan Pharmaceuticals: Sales Forecast, till 2030 (USD Million)
Figure 10.46 CBP-501, CanBas: Sales Forecast, till 2030 (USD Million)
Figure 10.47 Eprenetapopt (APR-246), Aprea Therapeutics: Sales Forecast, till 2030 (USD Million)
Figure 10.48 Irofulven, Allarity Therapeutics: Sales Forecast, till 2030 (USD Million)
Figure 10.49 LB-100, Lixte Biotechnology: Sales Forecast, till 2030 (USD Million)
Figure 10.50 Silmitasertib, Senhwa Biosciences: Sales Forecast, till 2030 (USD Million)
Figure 10.51 Global DNA Damage Response Targeting Therapeutics Market, Till 2035: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 11.1 Concluding Remarks: Market Landscape
Figure 11.2 Concluding Remarks: Clinical Trial Analysis
Figure 11.3 Concluding Remarks: Publications
Figure 11.4 Concluding Remarks: Key Parameters Impacting Drug Pricing and Adoption
Figure 11.5 Concluding Remarks: Market Forecast

Product Code: RA100280

GLOBAL DNA DAMAGE RESPONSE MARKET: OVERVIEW

As per Roots Analysis, the global DNA damage response market valued at USD 13 million in the current year is anticipated to grow at a lucrative CAGR during the forecast period.

The market sizing and opportunity analysis has been segmented across the following parameters:

Target Disease Indication

Acute Myeloid Leukemias
COVID-19
Diabetic Macular Edemas
Mesotheliomas
Myelodysplastic Syndromes
Non-Squamous Non-Small Cell Lung Cancers
Prostate Cancers
Uterine Serous Carcinomas

Therapeutic Area

Hematological Malignancies
Solid Tumors
Other Disorders

Target Molecule

APE1/Ref-1
Casein Kinase 2
CHK-1
C-Tak
DHODH
MAPKAPK2
p53
WEE 1

Type of Molecule

Biologics
Small Molecule

Route of Administration

Oral Drugs
Intravenous Drugs

Key Geographical Regions

North America (US and Canada)
Europe (Denmark, France, Germany, Italy, Spain and UK)
Asia-Pacific (Australia, Singapore and South Korea)

GLOBAL DNA DAMAGE RESPONSE MARKET: GROWTH AND TRENDS

The DNA damage response (DDR) consists of a coordinated network of pathways that not only facilitate the repair of DNA lesions but also activate cell cycle checkpoints. This leads to cell cycle arrest at critical stages in order to maintain the overall genomic integrity. Notably, if the damage is irreparable, this intricate system ensures that cells either repair their genetic material before undergoing division or facilitate programmed cell death to prevent the propagation of mutations. Further, its high specificity and sensitivity to conventional therapies, and low off-target toxicity have made DDR a promising therapeutic target for a broad range of clinical conditions, including both oncological and non-oncological diseases. Consequently, researchers worldwide are developing DDR inhibitors to counter DDR-mediated resistance to DNA-damaging anticancer therapies and to exploit DDR dysfunction in cancer by targeting alternative pathways.

It is worth mentioning that four poly-ADP ribose polymerase (PARP) inhibitor drugs, which target the DNA damage repair process, are currently approved for advanced-stage cancer treatment. Additionally, drug developers worldwide are investigating other molecular targets within the DNA damage response pathway, including ATM, ATR, CHK1, and WEE1.

GLOBAL DNA DAMAGE RESPONSE MARKET: KEY INSIGHTS

The report delves into the current state of global DNA damage response market and identifies potential growth opportunities within industry. Some key findings from the report include:

Presently, close to 45 companies are engaged in the development of DNA damage response (DDR) targeting therapeutics in order to treat a range of clinical conditions.
Majority of pipeline drug candidates are in the early phases of development; these are predominantly designed to target epitopes on biological molecules that are a characteristic of various oncological disorders.
The preclinical pipeline of DDR targeting therapeutics is substantial and growing; majority of these drug candidates (over 75%) are small molecules.
Over 70% of drug candidates targeting ATR are in clinical trials and around 55% of such interventions are designed for oral administration.
About 65% of DDR targeting drugs intended to treat solid tumors have already demonstrated preclinical proof of concept.
Since 2010, over 220 clinical trials have been registered to evaluate the efficacy of DDR targeting therapies; average completion time for such studies was relatively less in Asia-Pacific.

Innovation in this field is evident across the plethora of scientific articles published in prestigious journals; the current focus appears to be on identification of novel targets, specifically against different types of cancers.
The number of publications in this domain has increased significantly in the past one year; around 30% of the articles have been published since 2021.
Published articles / papers indicate that the focus of current research activity is on target molecules, such as ATR, ADP, ATR and HSP.
There has been an evident increase in research focused on DDR targeting therapies against cancers, such as leukemia, lung and ovarian cancers.
Several parameters, ranging from initial stages of development to launch of the drug, influence the pricing and adoption rates; developers must consider the combination of all these factors to survive the competition.
In pursuit of a competitive edge and the successful establishment of a large consumer base, it is imperative for innovators to understand both direct and indirect influences on the adoption and pricing of their respective products.
Considering the promising development pipeline of therapies and encouraging clinical research outcomes, the DDR targeting therapeutics market is anticipated to grow at a significant annualized till 2035.
The projected market opportunity is likely to be well-distributed across different target disease indications, routes of administration and key geographical regions.

Example Players in the DNA Damage Response Market

Aprea Therapeutics
AstraZeneca
Chordia Therapeutics
Mission Therapeutics
Repare Therapeutics
Senhwa Biosciences

GLOBAL DNA DAMAGE RESPONSE MARKET

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global DNA damage response market, focusing on key market segments, including [A] target disease indication, [B] therapeutic area, [C] target molecule, [D] type of molecule, [E] route of administration and [F] key geographical regions.
Market Landscape: A comprehensive evaluation of DNA damage response targeting therapeutics, considering various parameters, such as [A] phase of development, [B] target disease indication(s), [C] therapeutic area, [D] target molecule, [E] type of molecule, [F] type of therapy, [G] dosage form, [H] route of administration and [I] special drug designation awarded (if any). Additionally, a comprehensive evaluation of the companies engaged in development of DNA damage response targeting therapeutics, based on [A] year of establishment, [B] company size (in terms of employee count) and [C] location of respective headquarters.
Key Insights: An insightful analysis of contemporary market trends that have been depicted using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in DNA damage response market, [B] an analysis of DNA damage response targeting therapeutics developers, based on their target therapeutic area and company size, [C] a detailed analysis highlighting the regional distribution of developers engaged in DNA damage response market, and [D] a comprehensive analysis illustrating the distribution of DNA damage response targeting therapeutics.
Company Profiles: In-depth profiles of companies engaged in the development of DNA damage response targeting therapeutics, focusing on [A] company overview, [B] details related to its respective drug candidates and [C] recent developments and an informed future outlook.
Clinical Trial Analysis: An in-depth analysis of more than 250 completed, ongoing and planned clinical studies of various DNA damage response targeting therapeutics, based on various relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] gender of patients enrolled, [D] trial phase, [E] recruitment status and study design, leading [F] sponsors / collaborators and leading players (in terms of number of trials conducted), [G] type of organization, [H] popular therapeutic areas and [I] regional distribution of trials.
Publication Analysis: An insightful analysis of more than 150 peer-reviewed scientific articles related to DNA damage response targeting therapeutics, based on [A] year of publication, [B] type of publication, [C] key research hubs, [D] most popular authors, [E] provision of grant awarded, [F] target molecule, and [G] most popular journals.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
- 1.2.1. Research Assumptions
- 1.2.2. Project Methodology
- 1.2.3. Forecast Methodology
- 1.2.4. Robust Quality Control
- 1.2.5. Key Considerations
  - 1.2.5.1. Demographics
  - 1.2.5.2. Economic Factors
  - 1.2.5.3. Government Regulations
  - 1.2.5.4. Supply Chain
  - 1.2.5.5. COVID Impact / Related Factors
  - 1.2.5.6. Market Access
  - 1.2.5.7. Healthcare Policies
  - 1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of DNA Damage
3.3. DNA Damaging Agents
3.4. DNA Damage Response Systems
- 3.4.1. Key Components of DNA Repair Pathways
3.5. Types of DNA Repair Pathways
- 3.5.1. Direct Pathways
- 3.5.2. Excision Repair Pathway
  - 3.5.2.1. Base Excision Repair Pathway
  - 3.5.2.2. Nucleotide Excision Repair Pathway
  - 3.5.2.3. Mismatch Repair Pathway
- 3.5.3. Indirect Pathways
  - 3.5.3.1. Homologous Recombination (HR) Repair Pathway
  - 3.5.3.2. Non-homologous End Joining (NHEJ) Repair Pathway
3.6. Concluding Remarks

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. DNA Damage Response Targeting Therapeutics: Clinical Pipeline
- 4.2.1. Analysis by Phase of Development
- 4.2.2. Analysis by Target Disease Indication(s)
- 4.2.3. Analysis by Therapeutic Area
- 4.2.4. Analysis by Target Molecule
- 4.2.5. Analysis by Type of Molecule
- 4.2.6. Analysis by Type of Therapy
- 4.2.7. Analysis by Dosage Form
- 4.2.8. Analysis by Route of Administration
- 4.2.9. Analysis by Special Drug Designation Awarded
4.3. DNA Damage Response Targeting Therapeutics: Preclinical Pipeline
- 4.3.1. Analysis by Phase of Development
- 4.3.2. Analysis by Target Disease Indication(s)
- 4.3.3. Analysis by Therapeutic Area
- 4.3.4. Analysis by Type of Molecule
- 4.3.5. Analysis by Type of Therapy
4.4 DNA Damage Response Targeting Therapeutics: List of Developers
- 4.4.1. Analysis by Year of Establishment
- 4.4.2. Analysis by Company Size
- 4.4.3. Analysis by Location of Headquarters
- 4.4.4. Leading Developers: Analysis by Number of Proprietary Product Candidates

5. KEY INSIGHTS

5.1. Chapter Overview
5.2. Analysis by Portfolio Strength, Phase of Development and Company Size (4D Bubble Chart)
5.3. Analysis by Therapeutic Area and Company Size (Treemap Representation)
5.4. Analysis by Location of Headquarters (World Map Representation)
5.5. Analysis by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration (Grid Representation)

6. COMPANY PROFILES

6.1. Chapter Overview
6.2. Aprea Therapeutics
- 6.2.1. Company Overview
- 6.2.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.2.3. Recent Developments and Future Outlook
6.3. AstraZeneca
- 6.3.1. Company Overview
- 6.3.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.3.3. Recent Developments and Future Outlook
6.4. Chordia Therapeutics
- 6.4.1. Company Overview
- 6.4.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.4.3. Recent Developments and Future Outlook
6.5. Mission Therapeutics
- 6.5.1. Company Overview
- 6.5.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.5.3. Recent Developments and Future Outlook
6.6. Repare Therapeutics
- 6.6.1. Company Overview
- 6.6.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.6.3. Recent Developments and Future Outlook
6.7. Senhwa Biosciences
- 6.7.1. Company Overview
- 6.7.2. DNA Damage Response Targeting Therapeutics Portfolio
- 6.7.3. Recent Developments and Future Outlook

7. CLINICAL TRIALS ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. DNA Damage Response Targeting Therapeutics: Clinical Trial Analysis
- 7.3.1. Analysis by Trial Registration Year
- 7.3.2. Analysis by Number of Patients Enrolled
- 7.3.3. Analysis by Gender of Patients Enrolled
- 7.3.4. Analysis by Trial Phase
- 7.3.5. Analysis by Recruitment Status
- 7.3.6. Analysis by Study Design
- 7.3.7. Analysis by Type of Sponsor / Collaborator
- 7.3.8. Analysis by Therapeutic Area
- 7.3.9. Reginal Analysis
- 7.3.10. Case Study
- 7.3.11. Most Active Industry Players: Analysis by Number of Clinical Trails
- 7.3.12. Concluding Remarks

8. PUBLICATION ANALYSIS

8.1. Chapter Overview
8.2. Scope and Methodology
8.3. DNA Damage Response Targeting Therapeutics: List of Recent Publications
- 8.3.1. Analysis by Year of Publication
- 8.3.2. Analysis by Type of Publication
- 8.3.3. Emerging Focus Areas
- 8.3.4. Analysis by Key Research Journals
  - 8.3.4.1. Most Prominent Journals: Analysis by Number of Publications
  - 8.3.4.2. Analysis by Journal Impact Factor
  - 8.3.4.3. Most Prominent Journals: Analysis by Journal Impact Factor
- 8.3.5. Analysis by Key Research Hubs
- 8.3.6. Analysis by Target Molecule
  - 8.3.6.1. Most Popular Target Molecule: Analysis by Number of Publications
  - 8.3.6.2. Analysis by Year and Target Molecule
- 8.3.7. Analysis by Grants Awarded
  - 8.3.7.1. Locations of Grant Awarding Organizations: Analysis by Number of Publications
- 8.3.8. Publication Benchmarking Analysis

9. ANALYSIS OF KEY PARAMETERS IMPACTING DRUG PRICING AND ADOPTION

9.1. Chapter Overview
9.2. Key Market Drivers
9.3. Roots Analysis Framework
- 9.3.1. Benchmarking Parameters
- 9.3.2. Methodology
- 9.3.3. Impact on Price and Adoption
- 9.3.4. Impact on Pricing and Adoption of Individual Drugs / Drug Candidates
  - 9.3.4.1. Adavosertib
  - 9.3.4.2. APX3330
  - 9.3.4.3. ASLAN003
  - 9.3.4.4. CBP-501
  - 9.3.4.5. Eprenetapopt
  - 9.3.4.6. Irofulven
  - 9.3.4.7. LB-100
  - 9.3.4.8. Silmitasertib
  - 9.3.4.9. TRC-102
- 9.3.5. Concluding Remarks

10. MARKET FORECAST

10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Forecast Methodology and Key Assumptions
10.4. Global DNA Damage Response Targeting Therapeutics Market, Till 2035
- 10.4.1. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication
  - 10.4.1.1. DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, Till 2035
  - 10.4.1.2. DNA Damage Response Targeting Therapeutics Market for COVID-19, Till 2035
  - 10.4.1.3. DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, Till 2035
  - 10.4.1.4. DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, Till 2035
  - 10.4.1.5. DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, Till 2035
  - 10.4.1.6. DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, Till 2035
  - 10.4.1.7. DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, Till 2035
  - 10.4.1.8. DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, Till 2035
- 10.4.2. DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area
  - 10.4.2.1. DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, Till 2035
  - 10.4.2.2. DNA Damage Response Targeting Therapeutics Market for Solid Tumors, Till 2035
  - 10.4.2.3. DNA Damage Response Targeting Therapeutics Market for Other Disorders, Till 2035
- 10.4.3. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule
  - 10.4.3.1. DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, Till 2035
  - 10.4.3.2. DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, Till 2035
  - 10.4.3.3. DNA Damage Response Targeting Therapeutics Market for CHK-1, Till 2035
  - 10.4.3.4. DNA Damage Response Targeting Therapeutics Market for C-Tak, Till 2035
  - 10.4.3.5. DNA Damage Response Targeting Therapeutics Market for DHODH, Till 2035
  - 10.4.3.6. DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, Till 2035
  - 10.4.3.7. DNA Damage Response Targeting Therapeutics Market for p53, Till 2035
  - 10.4.3.8. DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, Till 2035
  - 10.4.3.9. DNA Damage Response Targeting Therapeutics Market for WEE1, Till 2035
- 10.4.4. DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule
  - 10.4.4.1. DNA Damage Response Targeting Therapeutics Market for Biologics, Till 2035
  - 10.4.4.2. DNA Damage Response Targeting Therapeutics Market for Small Molecules, Till 2035
- 10.4.5. DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration
  - 10.4.5.1. DNA Damage Response Targeting Therapeutics Market for Oral Drugs, Till 2035
  - 10.4.5.2. DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, Till 2035
- 10.4.6. DNA Damage Response Targeting Therapeutics Market: Distribution by Geography
  - 10.4.6.1. DNA Damage Response Targeting Therapeutics Market in the US, Till 2035
  - 10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Canada, Till 2035
  - 10.4.6.3. DNA Damage Response Targeting Therapeutics Market in Denmark, Till 2035
  - 10.4.6.4. DNA Damage Response Targeting Therapeutics Market in France, Till 2035
  - 10.4.6.5. DNA Damage Response Targeting Therapeutics Market in Germany, Till 2035
  - 10.4.6.6. DNA Damage Response Targeting Therapeutics Market in Italy, Till 2035
  - 10.4.6.7. DNA Damage Response Targeting Therapeutics Market in Spain, Till 2035
  - 10.4.6.8. DNA Damage Response Targeting Therapeutics Market in the UK, Till 2035
  - 10.4.6.9. DNA Damage Response Targeting Therapeutics Market in Australia, Till 2035
  - 10.4.6.10. DNA Damage Response Targeting Therapeutics Market in Singapore, Till 2035
  - 10.4.6.11. DNA Damage Response Targeting Therapeutics Market in South Korea, Till 2035
- 10.4.7. Drug-wise Sales Forecast
  - 10.4.7.1 Adavosertib (AZD1775, MK-1775), AstraZeneca
    - 10.4.7.1.1. Target Patient Population
    - 10.4.7.1.2. Sales Forecast
    - 10.4.7.1.3. Net Present Value
    - 10.4.7.1.4. Value Creation Analysis
  - 10.4.7.2. APX3330, Apexian Pharmaceuticals
    - 10.4.7.2.1. Target Patient Population
    - 10.4.7.2.2. Sales Forecast
    - 10.4.7.2.3. Net Present Value
    - 10.4.7.2.4. Value Creation Analysis
  - 10.4.7.3. ASLAN003 (LAS 186323), Aslan Pharmaceuticals
    - 10.4.7.3.1. Target Patient Population
    - 10.4.7.3.2. Sales Forecast
    - 10.4.7.3.3. Net Present Value
    - 10.4.7.3.4. Value Creation Analysis
  - 10.4.7.4. CBP-501, CanBas
    - 10.4.7.4.1. Target Patient Population
    - 10.4.7.4.2. Sales Forecast
    - 10.4.7.4.3. Net Present Value
    - 10.4.7.4.4. Value Creation Analysis
  - 10.4.7.5. Eprenetapopt, Aprea Therapeutics
    - 10.4.7.5.1. Target Patient Population
    - 10.4.7.5.2. Sales Forecast
    - 10.4.7.5.3. Net Present Value
    - 10.4.7.5.4. Value Creation Analysis
  - 10.4.7.6. Irofulven, Allarity Therapeutics
    - 10.4.7.6.1. Target Patient Population
    - 10.4.7.6.2. Sales Forecast
    - 10.4.7.6.3. Net Present Value
    - 10.4.7.6.4. Value Creation Analysis
  - 10.4.7.7. LB-100 (Lixte Biotechnology)
    - 10.4.7.7.1. Target Patient Population
    - 10.4.7.7.2. Sales Forecast
    - 10.4.7.7.3. Net Present Value
    - 10.4.7.7.4. Value Creation Analysis
  - 10.4.7.8. Silmitasertib, Senhwa Biosciences
    - 10.4.7.8.1. Target Patient Population
    - 10.4.7.8.2. Sales Forecast
    - 10.4.7.8.3. Net Present Value
    - 10.4.7.8.4. Value Creation Analysis
- 10.4.9 Concluding Remarks

DNA損傷応答市場：業界動向と世界の予測 - 適応疾患別、治療領域別、標的分子別、分子タイプ別、投与経路別、主要地域別

DNA Damage Response Market: Industry Trends and Global Forecasts - Distribution by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of Administration, and Key Geographical Regions

世界のDNA損傷応答市場：概要

世界のDNA損傷応答市場：成長と動向

世界のDNA損傷応答市場：主要インサイト

DNA損傷応答市場の参入企業例

世界のDNA損傷応答市場

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場情勢

第5章 重要な洞察

第6章 企業プロファイル

第7章 臨床試験の分析

第8章 出版物の分析

第9章 医薬品の価格と採用に影響を与える主要なパラメータの分析

第10章 市場予測

第11章 結論

第12章 付録I：表形式データ

第13章 付録II：企業および組織の一覧